Screener
Sutro Biopharma STRO Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Sutro Biopharma’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224170
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Interest income | 1,635 | 3,189 |
| Non-cash interest expense related to the sale of future royalties | (9,467) | (9,344) |
| Interest and other income (expense), net | (1,011) | (1,292) |
| Loss before provision for income taxes | (38,499) | (75,961) |
| (Benefit) from / provision for income taxes | (15) | 7 |
| Net loss | $(38,484) | $(75,968) |
| Net loss per share, basic and diluted | $(2.94) | $(9.08) |
| Weighted-average shares used in computing basic and diluted net loss per share | 13,082,355 | 8,364,294 |
Item 1. Financial Statements.
FAQ
- What is Sutro Biopharma's net income?
- Sutro Biopharma (STRO) reported net income of -$38.48M in Q1 2026.
- How has Sutro Biopharma's net income changed year-over-year?
- Sutro Biopharma's net income increased by 49.3% year-over-year, from -$75.97M to -$38.48M.
- What is the long-term trend for Sutro Biopharma's net income?
- Over 3 years (2021 to 2025), Sutro Biopharma's net income has grown at a 21.9% compound annual growth rate (CAGR), from -$105.54M to -$191.09M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Sutro Biopharma's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude